CN115583898A - A kind of preparation method of aryl isothiocyanate - Google Patents

A kind of preparation method of aryl isothiocyanate Download PDF

Info

Publication number
CN115583898A
CN115583898A CN202210791874.8A CN202210791874A CN115583898A CN 115583898 A CN115583898 A CN 115583898A CN 202210791874 A CN202210791874 A CN 202210791874A CN 115583898 A CN115583898 A CN 115583898A
Authority
CN
China
Prior art keywords
compound
solvent
reaction
formula
reagent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202210791874.8A
Other languages
Chinese (zh)
Inventor
童友之
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Suzhou Kintor Pharmaceuticals Inc
Original Assignee
Suzhou Kintor Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suzhou Kintor Pharmaceuticals Inc filed Critical Suzhou Kintor Pharmaceuticals Inc
Publication of CN115583898A publication Critical patent/CN115583898A/en
Pending legal-status Critical Current

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C253/00Preparation of carboxylic acid nitriles
    • C07C253/14Preparation of carboxylic acid nitriles by reaction of cyanides with halogen-containing compounds with replacement of halogen atoms by cyano groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C209/00Preparation of compounds containing amino groups bound to a carbon skeleton
    • C07C209/68Preparation of compounds containing amino groups bound to a carbon skeleton from amines, by reactions not involving amino groups, e.g. reduction of unsaturated amines, aromatisation, or substitution of the carbon skeleton
    • C07C209/74Preparation of compounds containing amino groups bound to a carbon skeleton from amines, by reactions not involving amino groups, e.g. reduction of unsaturated amines, aromatisation, or substitution of the carbon skeleton by halogenation, hydrohalogenation, dehalogenation, or dehydrohalogenation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C331/00Derivatives of thiocyanic acid or of isothiocyanic acid
    • C07C331/16Isothiocyanates
    • C07C331/28Isothiocyanates having isothiocyanate groups bound to carbon atoms of six-membered aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C335/00Thioureas, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C335/04Derivatives of thiourea
    • C07C335/16Derivatives of thiourea having nitrogen atoms of thiourea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C335/22Derivatives of thiourea having nitrogen atoms of thiourea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by carboxyl groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Health & Medical Sciences (AREA)
  • Toxicology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

The invention belongs to the technical field of pharmaceutical chemicals, and particularly relates to a preparation method of aryl isothiocyanate. The aryl bromide and the cyanation reagent are used as raw materials to carry out cyanation reaction, aryl nitrile is obtained through a one-step method, and then aryl isothiocyanate is generated through reaction with a non-thiophosgene reagent. The preparation process of the invention does not need protection of acetyl protecting group, thus reducing reaction steps and greatly improving atom economy and total reaction yield; and a technical scheme for preparing aryl isothiocyanate by removing thiophosgene is provided in the reaction process, so that the method is more environment-friendly and is suitable for industrial large-scale production.

Description

一种异硫氰酸芳基酯的制备方法A kind of preparation method of aryl isothiocyanate

技术领域technical field

本发明属于医药化工技术领域,具体涉及一种异硫氰酸芳基酯的制备方法。The invention belongs to the technical field of medicine and chemical industry, and in particular relates to a preparation method of aryl isothiocyanate.

背景技术Background technique

异硫氰酸芳基酯是一类重要的医药中间体,广泛用于制备硫代乙内酰脲类结构的雄激素受体拮抗剂,如恩杂鲁胺(Enzalutamide)、阿帕他胺(Apalutamide)和普克鲁胺(Pruxelutamide)。Aryl isothiocyanate is a class of important pharmaceutical intermediates, widely used in the preparation of androgen receptor antagonists of thiohydantoin structure, such as enzalutamide (Enzalutamide), apalutamide ( Apalutamide) and Pruxelutamide.

式A化合物为制备普克鲁胺(Pruxelutamide)的中间体,申请人在CN103608333B中公开了其制备方法,合成路线如下:The compound of formula A is an intermediate for preparing Pruxelutamide, and the applicant has disclosed its preparation method in CN103608333B, and the synthetic route is as follows:

Figure BDA0003730560390000011
Figure BDA0003730560390000011

反应路线中以化合物11为原料,经过多步骤反应生成式A化合物。在制备化合物15时,必须采用乙酰基对相应氨基进行保护,然后进行氰基化,脱保护。最后,化合物15与硫光气反应生成目标产物。In the reaction scheme, compound 11 is used as a raw material to generate the compound of formula A through multi-step reactions. When preparing compound 15, the corresponding amino group must be protected with acetyl group, followed by cyanation and deprotection. Finally, compound 15 reacted with thiophosgene to generate the target product.

上述路线存在以下缺陷:1)反应过程中需要对氨基进行保护和脱保护,反应步骤冗长,导致总收率较低(说明书[0483]-[0493]段中记载的化合物11通过溴代、氨基保护、氰基化、脱保护四步反应得到化合物15的总收率为75%×85%×80%×90%=45.9%),且原子经济性差;2)硫光气对环境不友好,不利于生产放大。The above route has the following defects: 1) the amino group needs to be protected and deprotected during the reaction, and the reaction steps are tedious, resulting in a lower overall yield (compound 11 recorded in the section [0483]-[0493] of the description is passed through bromination, amino The total yield of compound 15 obtained by the four-step reaction of protection, cyanation and deprotection is 75%×85%×80%×90%=45.9%), and the atom economy is poor; 2) Thiophosgene is not friendly to the environment, Not conducive to production scale-up.

临床实验结果表明,普克鲁胺(Pruxelutamide)可用于治疗COVID-19,所以目前需要克服现有技术中的缺陷,提供一条适合工业化生产的路线,以制备普克鲁胺的中间体异硫氰酸芳基酯化合物,即式A化合物。The results of clinical trials show that proxalutamide (Pruxelutamide) can be used to treat COVID-19, so it is necessary to overcome the defects in the prior art and provide a route suitable for industrial production to prepare the intermediate isothiocyanate of proxalutamide Acid aryl ester compound, namely formula A compound.

发明内容Contents of the invention

发明要解决的问题The problem to be solved by the invention

为了解决现有技术中的问题,本发明提供了一种制备异硫氰酸芳基酯的方法,本发明采用一步法进行氰基化反应,无需对氨基进行保护;且在反应过程中提出了革除硫光气制备异硫氰酸芳基酯的技术方案,环境更为友好。In order to solve the problems in the prior art, the present invention provides a kind of method for preparing aryl isothiocyanate, the present invention adopts one-step method to carry out cyanation reaction, does not need to protect amino group; And proposed in the reaction process Eliminate the technical scheme of preparing aryl isothiocyanate from thiophosgene, and the environment is more friendly.

用于解决问题的方案solutions to problems

根据本发明的第一个方面,本发明提供了一种制备化合物15的方法,所述方法包括化合物12在溶剂和氰基化试剂的存在下反应生成化合物15,反应方程式如下:According to the first aspect of the present invention, the present invention provides a method for preparing compound 15, said method comprising the reaction of compound 12 to generate compound 15 in the presence of a solvent and a cyanation reagent, the reaction equation is as follows:

Figure BDA0003730560390000021
Figure BDA0003730560390000021

优选地,所述溶剂为极性有机溶剂;所述极性有机溶剂选自腈类、亚砜类、链状酰胺类或环状酰胺类中任意一种或多种的组合,优选为N,N-二甲基甲酰胺、N,N-二甲基乙酰胺、二甲基亚砜、乙腈或N-甲基吡咯烷酮中任意一种或多种的组合,进一步优选为N,N-二甲基甲酰胺。Preferably, the solvent is a polar organic solvent; the polar organic solvent is selected from any one or more combinations of nitriles, sulfoxides, chain amides or cyclic amides, preferably N, A combination of any one or more of N-dimethylformamide, N,N-dimethylacetamide, dimethyl sulfoxide, acetonitrile or N-methylpyrrolidone, more preferably N,N-dimethyl base formamide.

优选地,所述氰基化试剂选自KCN、NaCN、CuCN、Zn(CN)2、Ni(CN)2、K4[Fe(CN)6]或K3[Fe(CN)6]中任意一种,进一步优选为CuCN。Preferably, the cyanation agent is selected from any of KCN, NaCN, CuCN, Zn(CN) 2 , Ni(CN) 2 , K 4 [Fe(CN) 6 ] or K 3 [Fe(CN) 6 ] One, more preferably CuCN.

优选地,所述溶剂为N,N-二甲基甲酰胺,所述氰基化试剂为CuCN。Preferably, the solvent is N,N-dimethylformamide, and the cyanation agent is CuCN.

优选地,所述方法包括将化合物12滴加到溶剂(优选N,N-二甲基甲酰胺)和氰基化试剂(优选CuCN)的体系中,滴加结束后升温反应。Preferably, the method includes adding compound 12 dropwise into a system of a solvent (preferably N,N-dimethylformamide) and a cyanation agent (preferably CuCN), and heating up the reaction after the dropwise addition.

优选地,滴加过程中控制体系温度;更优选地,所述体系温度为10-50℃,优选为10-40℃或15-35℃,进一步优选20-30℃。Preferably, the system temperature is controlled during the dropping process; more preferably, the system temperature is 10-50°C, preferably 10-40°C or 15-35°C, further preferably 20-30°C.

优选地,所述氰基化试剂的摩尔量为化合物12的1.0-1.5倍,优选1.1、1.2、1.3或1.4倍,进一步优选1.1倍。Preferably, the molar amount of the cyanation reagent is 1.0-1.5 times that of compound 12, preferably 1.1, 1.2, 1.3 or 1.4 times, more preferably 1.1 times.

优选地,所述反应的温度为110-140℃,优选110-130℃,进一步优选120-130℃。Preferably, the reaction temperature is 110-140°C, preferably 110-130°C, more preferably 120-130°C.

优选地,所述方法还包括后处理的步骤,所述后处理的步骤包括:向反应体系中加入有机相溶剂和水相溶剂,萃取,洗涤,浓缩有机相,即得。优选地,所述有机相溶剂为氯代烃,优选二氯甲烷;所述水相溶剂为水。Preferably, the method further includes a post-treatment step, and the post-treatment step includes: adding an organic phase solvent and an aqueous phase solvent to the reaction system, extracting, washing, and concentrating the organic phase to obtain the product. Preferably, the organic phase solvent is chlorinated hydrocarbon, preferably dichloromethane; the aqueous phase solvent is water.

优选地,所述后处理的步骤包括:向反应体系中加入有机相溶剂和水相溶剂,萃取,洗涤,浓缩有机相,打浆,即得。优选地,所述有机相溶剂为氯代烃,优选二氯甲烷;所述水相溶剂为氨水;所述打浆采用烷烃来完成,优选正庚烷。Preferably, the post-processing step includes: adding an organic phase solvent and an aqueous phase solvent to the reaction system, extracting, washing, concentrating the organic phase, and beating to obtain the product. Preferably, the organic phase solvent is a chlorinated hydrocarbon, preferably dichloromethane; the aqueous phase solvent is ammonia water; and the beating is done using alkanes, preferably n-heptane.

通过调整该步反应中的加料顺序、加料方式、滴加温度和反应温度等参数,由化合物12通过一步反应即可得到化合物15,且使得该步反应的收率大大提高。并且,发明人优化了后处理步骤,采用加入氨水萃取和打浆工艺,在保证高收率的前提下,使得产物的纯度也得到很大提高。Compound 15 can be obtained from compound 12 through one-step reaction by adjusting the order of addition, method of addition, dropwise addition temperature, and reaction temperature in this step reaction, and the yield of this step reaction is greatly improved. Moreover, the inventor optimized the post-processing steps, and adopted the extraction and beating process by adding ammonia water, so that the purity of the product was also greatly improved under the premise of ensuring a high yield.

进一步地,所述制备化合物15的方法中,化合物12的制备方法包括:化合物11在有机溶剂和溴化试剂的存在下反应生成化合物12,反应方程式如下:Further, in the method for preparing compound 15, the preparation method of compound 12 comprises: reacting compound 11 in the presence of an organic solvent and a brominating reagent to generate compound 12, and the reaction equation is as follows:

Figure BDA0003730560390000031
Figure BDA0003730560390000031

优选地,所述有机溶剂为链状或环状酰胺类中任意一种或多种的组合,优选N,N-二甲基甲酰胺或N,N-二甲基乙酰胺中的一种或两种的组合,更优选N,N-二甲基甲酰胺。Preferably, the organic solvent is any one or a combination of chain or cyclic amides, preferably one or more of N,N-dimethylformamide or N,N-dimethylacetamide A combination of the two, more preferably N,N-dimethylformamide.

优选地,所述溴化试剂为N-溴代丁二酰亚胺(NBS)、1,3-二溴-5,5-二甲基海因(DBH)、3,5-二溴苯甲醛(DBBA)、N-溴代邻苯二甲酰亚胺(NBP)或1,3,5-三溴-1,3,5-三嗪-2,4,6-三酮(TBCA)。Preferably, the bromination reagent is N-bromosuccinimide (NBS), 1,3-dibromo-5,5-dimethylhydantoin (DBH), 3,5-dibromobenzaldehyde (DBBA), N-bromophthalimide (NBP) or 1,3,5-tribromo-1,3,5-triazine-2,4,6-trione (TBCA).

优选地,所述方法包括将溴化试剂(优选NBS)或者溴化试剂和有机溶剂的体系(优选NBS和N,N-二甲基甲酰胺的体系)滴加到化合物11和有机溶剂(优选N,N-二甲基甲酰胺)的体系中,滴加结束后升温反应。Preferably, the method comprises adding a bromination reagent (preferably NBS) or a system of a bromination reagent and an organic solvent (preferably a system of NBS and N,N-dimethylformamide) to compound 11 and an organic solvent (preferably N,N-dimethylformamide) system, after the dropwise addition, the temperature rises to react.

优选地,滴加过程中控制体系温度;更优选地,所述体系温度为-5~5℃,进一步优选0℃(例如冰浴)。Preferably, the temperature of the system is controlled during the dropwise addition; more preferably, the temperature of the system is -5-5°C, further preferably 0°C (for example, an ice bath).

优选地,所述方法还包括后处理的步骤,所述后处理的步骤包括:向反应体系中加入淬灭剂的水溶液和有机相溶剂,萃取,浓缩有机相,即得。优选地,所述淬灭剂为亚硫酸氢盐,优选亚硫酸氢钠;所述有机相溶剂为酯,优选乙酸乙酯。Preferably, the method further includes a post-treatment step, and the post-treatment step includes: adding an aqueous solution of a quencher and an organic phase solvent to the reaction system, extracting, and concentrating the organic phase to obtain the product. Preferably, the quenching agent is bisulfite, preferably sodium bisulfite; the organic phase solvent is ester, preferably ethyl acetate.

而在CN103608333B中,该步反应的滴加过程并未控温,在室温下进行,该步反应的最终收率只有75%。并且,其后处理步骤是加入乙醚进行稀释,再用盐水进行洗涤,并未淬灭多余的NBS,若不纯化化合物12而直接进行氰基化反应,则多余的NBS可能会残留到氰基化反应中影响收率。However, in CN103608333B, the dropping process of this step reaction is not temperature-controlled, and is carried out at room temperature, and the final yield of this step reaction is only 75%. Moreover, the post-treatment step is to add diethyl ether for dilution, and then wash with brine, which does not quench the excess NBS. If the cyanation reaction is carried out directly without purifying compound 12, the excess NBS may remain in the cyanation reaction. affect the yield in the reaction.

进一步地,所述制备化合物15的方法的具体步骤为:Further, the specific steps of the method for preparing compound 15 are:

向反应瓶中加入N,N-二甲基甲酰胺、化合物11,搅拌溶解,冰浴条件下滴加NBS的N,N-二甲基甲酰胺溶液,滴加结束后自然升温至室温反应;反应结束后滴加亚硫酸氢钠水溶液,乙酸乙酯萃取,收集有机相,减压浓缩,得化合物12;Add N,N-dimethylformamide and compound 11 to the reaction flask, stir to dissolve, add NBS N,N-dimethylformamide solution dropwise under ice bath conditions, and naturally warm up to room temperature after the addition; After the reaction was completed, an aqueous solution of sodium bisulfite was added dropwise, extracted with ethyl acetate, the organic phase was collected and concentrated under reduced pressure to obtain compound 12;

向反应瓶中加入CuCN、N,N-二甲基甲酰胺,搅拌,将上述步骤所得化合物12滴加到反应瓶中,控制体系温度和滴加时间,滴加结束后升温反应;反应结束后降温至室温,加入氨水溶液和二氯甲烷搅拌,萃取,收集二氯甲烷层,饱和食盐水洗涤二氯甲烷层,收集有机层,浓缩,得粗品,粗品采用正庚烷打浆得化合物15;Add CuCN and N,N-dimethylformamide to the reaction flask, stir, add the compound 12 obtained in the above steps into the reaction flask dropwise, control the temperature of the system and the time of dropping, and raise the temperature to react after the addition; Cool down to room temperature, add ammonia solution and dichloromethane, stir, extract, collect the dichloromethane layer, wash the dichloromethane layer with saturated brine, collect the organic layer, and concentrate to obtain a crude product, which is beaten with n-heptane to obtain compound 15;

优选地,上述具体步骤中的反应温度、反应时间、反应试剂的摩尔比等参数如前述制备化合物12和化合物15的方法中所限定。Preferably, the parameters such as reaction temperature, reaction time, and molar ratio of reagents in the above specific steps are as defined in the aforementioned methods for preparing compound 12 and compound 15.

根据本发明的第二个方面,本发明提供了一种制备式A所示化合物的方法,所述方法包括:化合物15与非硫光气试剂在溶剂或非溶剂下反应生成式A所示化合物,反应方程式为:According to the second aspect of the present invention, the present invention provides a method for preparing the compound represented by formula A, the method comprising: reacting compound 15 with a non-thiophosgene reagent in a solvent or a non-solvent to generate the compound represented by formula A , the reaction equation is:

Figure BDA0003730560390000041
Figure BDA0003730560390000041

优选地,所述化合物15可以由第一个方面中所述方法制备而成。Preferably, the compound 15 can be prepared by the method described in the first aspect.

优选地,所述非硫光气试剂为N,N'-硫羰基二咪唑、二硫化碳、N,N-二甲基硫代氨基甲酰氯或硫代氯甲酸苯酯中任意一种。Preferably, the non-thiophosgene reagent is any one of N,N'-thiocarbonyldiimidazole, carbon disulfide, N,N-dimethylthiocarbamoyl chloride or phenyl thiochloroformate.

根据本发明的第三个方面,本发明提供了另一种制备式A所示化合物的方法,所述方法包括化合物12在溶剂和氰基化试剂的存在下反应生成化合物15,化合物15与非硫光气试剂在溶剂或非溶剂下反应生成式A所示化合物,反应方程式如下:According to the third aspect of the present invention, the present invention provides another method for preparing the compound shown in formula A, said method comprising reacting compound 12 in the presence of a solvent and a cyanation reagent to generate compound 15, compound 15 and non- Thiophosgene reagent reacts under solvent or non-solvent to generate the compound shown in formula A, and the reaction equation is as follows:

Figure BDA0003730560390000042
Figure BDA0003730560390000042

优选地,所述化合物15可以由第一个方面中的方法制备而成。Preferably, the compound 15 can be prepared by the method in the first aspect.

优选地,所述非硫光气试剂是指N,N'-硫羰基二咪唑、二硫化碳、N,N-二甲基硫代氨基甲酰氯或硫代氯甲酸苯酯,反应方程式如下:Preferably, the non-thiophosgene reagent refers to N,N'-thiocarbonyldiimidazole, carbon disulfide, N,N-dimethylthiocarbamoyl chloride or phenylthiochloroformate, and the reaction equation is as follows:

Figure BDA0003730560390000051
Figure BDA0003730560390000051

另外,申请人在前期研究中发现,通过控制反应条件,化合物15与非硫光气试剂可以生成一种新的关环产物:式I所示化合物或式II所示化合物。所以,本发明还提供了化合物15在制备式I所示化合物或式II所示化合物中的用途,其中,所述化合物15由第一个方面中所述方法制备而成。In addition, the applicant found in the previous research that by controlling the reaction conditions, compound 15 and non-thiophosgene reagents can generate a new ring-closing product: the compound shown in formula I or the compound shown in formula II. Therefore, the present invention also provides the use of compound 15 in preparing the compound shown in formula I or the compound shown in formula II, wherein the compound 15 is prepared by the method described in the first aspect.

Figure BDA0003730560390000052
Figure BDA0003730560390000052

以化合物15为原料,以N,N'-硫羰基二咪唑为反应试剂,在有机碱和有机溶剂的反应体系下反应,生成式I所示化合物,反应方程式如下:Using compound 15 as a raw material and N,N'-thiocarbonyldiimidazole as a reagent, react in a reaction system of an organic base and an organic solvent to generate a compound shown in formula I. The reaction equation is as follows:

Figure BDA0003730560390000053
Figure BDA0003730560390000053

优选地,所述化合物15可以由第一个方面中所述方法制备而成。Preferably, the compound 15 can be prepared by the method described in the first aspect.

优选地,所述有机碱为含氮有机碱;优选地,所述含氮有机碱为N,N-二异丙基乙胺(DIPEA)、N,N-二异丙基苯胺、4-二甲氨基吡啶(DMAP)、二甲基吡啶、咪唑、三乙胺或吡啶中的任意一种或两种以上,优选三乙胺和/或DMAP。Preferably, the organic base is a nitrogen-containing organic base; preferably, the nitrogen-containing organic base is N,N-diisopropylethylamine (DIPEA), N,N-diisopropylaniline, 4-di Any one or more of methylaminopyridine (DMAP), lutidine, imidazole, triethylamine or pyridine, preferably triethylamine and/or DMAP.

优选地,所述有机溶剂为卤代烃、芳烃、C2-C6腈,优选甲苯和/或乙腈。Preferably, the organic solvent is halogenated hydrocarbon, aromatic hydrocarbon, C2-C6 nitrile, preferably toluene and/or acetonitrile.

优选地,所述N,N'-硫羰基二咪唑的摩尔量为化合物15的1-3倍,优选2倍。Preferably, the molar amount of N,N'-thiocarbonyldiimidazole is 1-3 times, preferably 2 times, that of compound 15.

优选地,所述有机碱的摩尔量为化合物15的0.1-5倍,优选3倍。Preferably, the molar amount of the organic base is 0.1-5 times, preferably 3 times, that of compound 15.

优选地,所述反应的温度为反应温度为0℃至沸点以下,优选40℃至沸点以下,例如50-90℃,50-80℃,60-70℃或80~90℃。Preferably, the reaction temperature is from 0°C to below the boiling point, preferably from 40°C to below the boiling point, such as 50-90°C, 50-80°C, 60-70°C or 80-90°C.

同样地,以化合物15为原料,以二硫化碳为反应试剂,在有机碱和有机溶剂的反应体系下反应,生成式II所示化合物,反应方程式如下:Similarly, compound 15 is used as a raw material, and carbon disulfide is used as a reagent to react under the reaction system of an organic base and an organic solvent to generate a compound shown in formula II, and the reaction equation is as follows:

Figure BDA0003730560390000061
Figure BDA0003730560390000061

优选地,所述化合物15可以由第一个方面中所述方法制备而成。Preferably, the compound 15 can be prepared by the method described in the first aspect.

优选地,所述有机碱为三乙胺、吡啶、N,N-二异丙基乙胺(DIPEA)、三乙烯二胺(DABCO)、1,5-二氮杂双环[4.3.0]壬-5-烯(DBN)、1,8-二偶氮杂双螺环[5.4.0]十一-7-烯(DBU),4-二甲氨基吡啶(DMAP)、N-甲基吗啉、四甲基乙二胺或其混合物,更优选三乙烯二胺。Preferably, the organic base is triethylamine, pyridine, N,N-diisopropylethylamine (DIPEA), triethylenediamine (DABCO), 1,5-diazabicyclo[4.3.0]nonane -5-ene (DBN), 1,8-diazobispiro[5.4.0]undec-7-ene (DBU), 4-dimethylaminopyridine (DMAP), N-methylmorpholine , tetramethylethylenediamine or a mixture thereof, more preferably triethylenediamine.

优选地,所述有机溶剂为烷基酮类,优选地所述烷基酮为丙酮、丁酮或甲基异丁基酮,优选丙酮。Preferably, the organic solvent is an alkyl ketone, preferably the alkyl ketone is acetone, butanone or methyl isobutyl ketone, preferably acetone.

优选地,所述二硫化碳与化合物15的摩尔比为1-3倍,例如1.2、1.5或2.0倍,更优选1.2倍。Preferably, the molar ratio of carbon disulfide to compound 15 is 1-3 times, such as 1.2, 1.5 or 2.0 times, more preferably 1.2 times.

优选地,所述有机碱与化合物15的摩尔比为0.1-1倍,更优选为0.2-0.8倍(例如0.2,0.4,0.6,0.8),进一步优选0.4-0.5倍。Preferably, the molar ratio of the organic base to compound 15 is 0.1-1 times, more preferably 0.2-0.8 times (eg 0.2, 0.4, 0.6, 0.8), further preferably 0.4-0.5 times.

上述式I所示化合物或式II所示化合物可作为式A所示化合物制备过程中产生的杂质,用于式A所示化合物目标产品的质量控制,监控目标产品中式I所示化合物或式II所示化合物的含量,评价目标产品的质量。所以,本发明还提供了上述式I所示化合物或式II所示化合物或其制备方法在式A所示化合物的产品质量控制中的应用。The compound shown in the above formula I or the compound shown in the formula II can be used as the impurity produced in the preparation process of the compound shown in the formula A for the quality control of the target product of the compound shown in the formula A, and monitor the compound shown in the formula I or the formula II in the target product The content of the indicated compounds was used to evaluate the quality of the target product. Therefore, the present invention also provides the application of the compound represented by the above formula I or the compound represented by the formula II or the preparation method thereof in the product quality control of the compound represented by the formula A.

根据本发明的第四个方面,本发明提供了另一种制备式A所示化合物的方法,所述方法包括如下步骤:According to a fourth aspect of the present invention, the present invention provides another method for preparing the compound shown in formula A, said method comprising the steps of:

Figure BDA0003730560390000071
Figure BDA0003730560390000071

其中,P为氨基保护基;Wherein, P is an amino protecting group;

1)化合物15在硫氰酸盐和氨基保护剂的存在下生成化合物15-1;1) compound 15 generates compound 15-1 in the presence of thiocyanate and amino protecting agent;

优选地,所述化合物15可以由第一个方面中所述方法制备而成;Preferably, the compound 15 can be prepared by the method described in the first aspect;

优选地,所述硫氰酸盐为硫氰酸铵、硫氰酸钠、硫氰酸钾、硫氰酸镁或硫氰酸锰中任意一种,优选硫氰酸铵;Preferably, the thiocyanate is any one of ammonium thiocyanate, sodium thiocyanate, potassium thiocyanate, magnesium thiocyanate or manganese thiocyanate, preferably ammonium thiocyanate;

优选地,所述氨基保护基为烷氧羰基、酰基或烷基中的任意一种;进一步地,所述氨基保护基中的烷氧羰基可以被取代基取代或未被取代,所述取代基可以为芳基、烯基或烷基硅基;所述氨基保护基中的烷基可以被取代基取代或未被取代,所述取代基可以为芳基或被烷氧基取代的芳基;更进一步地,所述烷氧羰基为苄氧羰基Cbz、叔丁氧羰基Boc、芴甲氧羰基Fmoc、烯丙氧羰基Alloc或三甲基硅乙氧羰基Teoc中任意一种;所述酰基为邻苯二甲酰基Pht,对甲苯磺酰基Tos,三氟乙酰基Tfa或苯甲酰基Bz中任意一种,优选为苯甲酰基Bz;所述烷基为三苯甲基Trt,2,4-二甲氧基苄基Dmb,对甲氧基苄基Pmb或苄基Bn中任意一种;Preferably, the amino-protecting group is any one of alkoxycarbonyl, acyl or alkyl; further, the alkoxycarbonyl in the amino-protecting group may be substituted or unsubstituted, and the substituent It can be an aryl group, an alkenyl group or an alkylsilyl group; the alkyl group in the amino protecting group can be substituted or unsubstituted by a substituent, and the substituent can be an aryl group or an aryl group substituted by an alkoxy group; Furthermore, the alkoxycarbonyl group is any one of benzyloxycarbonyl Cbz, tert-butoxycarbonyl Boc, fluorenylmethoxycarbonyl Fmoc, allyloxycarbonyl Alloc or trimethylsilylethoxycarbonyl Teoc; the acyl group is Any one of phthaloyl Pht, p-toluenesulfonyl Tos, trifluoroacetyl Tfa or benzoyl Bz, preferably benzoyl Bz; the alkyl group is trityl Trt, 2,4- Any one of dimethoxybenzyl Dmb, p-methoxybenzyl Pmb or benzyl Bn;

2)化合物15-1脱除氨基保护基,生成化合物15-2;2) Compound 15-1 removes the amino protecting group to generate compound 15-2;

本领域普通技术人员可以根据保护基的不同,采用不同的脱保护基体系;优选地,化合物15-1可以在碱和溶剂的体系中脱除氨基保护基;所述碱为无机碱,优选碱金属氢氧化物,更优选为氢氧化钠或氢氧化钾;所述溶剂为醇类溶剂,优选甲醇、乙醇或异丙醇等;Those skilled in the art can use different deprotecting group systems according to different protecting groups; preferably, compound 15-1 can remove the amino protecting group in a system of base and solvent; the base is an inorganic base, preferably a base Metal hydroxide, more preferably sodium hydroxide or potassium hydroxide; The solvent is an alcoholic solvent, preferably methanol, ethanol or isopropanol, etc.;

3)化合物15-2脱除氨气,生成式A化合物;3) Compound 15-2 removes ammonia to generate a compound of formula A;

可以在高沸点的有机溶剂中加热脱除氨气,例如在甲苯、二甲苯、氯化苯、N,N-二甲基甲酰胺、N,N-二甲基乙酰胺、二甲基亚砜或N-甲基吡咯烷酮中脱除氨气;也可以在有机溶剂和水的混合体系中,添加酸式盐(硫酸氢钠、硫酸氢钾、亚硫酸氢钠、亚硫酸氢钾、磷酸二氢钠、磷酸二氢钾、草酸氢钠、草酸氢钾等中的一种或多种)催化反应进行脱除氨气。Ammonia can be removed by heating in high-boiling organic solvents, such as toluene, xylene, chlorinated benzene, N,N-dimethylformamide, N,N-dimethylacetamide, dimethyl sulfoxide or N-methylpyrrolidone to remove ammonia; it is also possible to add acid salts (sodium bisulfate, potassium bisulfate, sodium bisulfite, potassium bisulfite, dihydrogen phosphate in a mixed system of organic solvent and water) One or more of sodium, potassium dihydrogen phosphate, sodium hydrogen oxalate, potassium hydrogen oxalate, etc.) catalytic reaction to remove ammonia.

根据本发明的第五个方面,本发明提供了另一种制备式A所示化合物的方法,所述方法包括:化合物12在溶剂和氰基化试剂的存在下反应生成化合物15,化合物15通过第四个方面中所述的方法生成式A所示化合物,反应方程式如下:According to a fifth aspect of the present invention, the present invention provides another method for preparing the compound shown in formula A, the method comprising: reacting compound 12 in the presence of a solvent and a cyanation reagent to generate compound 15, and compound 15 is passed through The method described in the fourth aspect generates the compound shown in formula A, and the reaction equation is as follows:

Figure BDA0003730560390000081
Figure BDA0003730560390000081

其中,P为氨基保护基。Wherein, P is an amino protecting group.

优选地,所述化合物15可由第一个方面中的方法制备而成。Preferably, the compound 15 can be prepared by the method in the first aspect.

发明的效果The effect of the invention

与现有技术相比,本发明具有如下优点:Compared with prior art, the present invention has following advantage:

1)本发明以化合物12为原料,采用直接氰基化的方法,通过一步反应制备得到化合物15;革除了酰基保护基的保护,反应步骤减少,原子经济性大大提高;通过控制溴代和氰基化两步反应中的加料顺序、加料方式、加料温度、反应温度、后处理等条件,反应总收率可达80%,远远高于CN103608333B中的总收率(溴代、酰基保护、氰基化和脱保护四步反应总收率为45.9%);尤其是氰基化反应的后处理采用了氨水萃取洗涤和正庚烷热打浆的步骤,去除了大量杂质,在保证高收率的前提下,使产品纯度也得到了很大提升。1) The present invention uses compound 12 as a raw material, adopts a direct cyanation method, and prepares compound 15 through a one-step reaction; the protection of the acyl protecting group is removed, the reaction steps are reduced, and the atom economy is greatly improved; According to the conditions such as feeding order, feeding method, feeding temperature, reaction temperature and post-treatment in the two-step reaction of alkylation, the total yield of reaction can reach 80%, which is far higher than the total yield in CN103608333B (bromo, acyl protection, The total yield of cyanation and deprotection four-step reaction is 45.9%); especially the post-treatment of cyanation reaction has adopted the steps of ammonia water extraction washing and n-heptane thermal beating, which removes a large amount of impurities and ensures high yield Under the premise, the product purity has also been greatly improved.

2)本发明采用N,N'-硫羰基二咪唑、二硫化碳、N,N-二甲基硫代氨基甲酰氯、硫代氯甲酸苯酯或硫氰酸盐等试剂制备式A化合物,替代了硫光气,解决了硫光气环境污染大、不利于生产放大的缺陷。同时,本发明还提供了化合物15可与N,N'-硫羰基二咪唑或二硫化碳等试剂在特定的反应条件下生成的一种新的关环产物,该关环产物或其制备方法可应用于式A化合物产品的质量控制。2) The present invention uses reagents such as N,N'-thiocarbonyldiimidazole, carbon disulfide, N,N-dimethylthiocarbamoyl chloride, phenyl thiochloroformate or thiocyanate to prepare the compound of formula A, replacing Thiophosgene solves the disadvantages of thiophosgene that pollutes the environment and is not conducive to production scale-up. At the same time, the present invention also provides a new ring-closing product that compound 15 can form with reagents such as N,N'-thiocarbonyldiimidazole or carbon disulfide under specific reaction conditions. The ring-closing product or its preparation method can be applied to In the quality control of formula A compound product.

附图说明Description of drawings

图1为本发明实施例1制备的化合物的HPLC图谱。Figure 1 is the HPLC spectrum of the compound prepared in Example 1 of the present invention.

图2为本发明实施例2制备的化合物的LC-MS图谱。Figure 2 is the LC-MS spectrum of the compound prepared in Example 2 of the present invention.

图3为本发明实施例2制备的化合物的核磁共振氢谱图。Figure 3 is the H NMR spectrum of the compound prepared in Example 2 of the present invention.

图4为本发明实施例3制备的化合物的LC-MS图谱。Figure 4 is the LC-MS spectrum of the compound prepared in Example 3 of the present invention.

具体实施方式detailed description

本发明中的“式A化合物”、“式A所示化合物”或“式A所示异硫氰酸芳基酯化合物”均是指具有以下结构的化合物,其为普克鲁胺(Pruxelutamide)的中间体。"Compound of formula A", "compound shown in formula A" or "aryl isothiocyanate compound shown in formula A" in the present invention all refer to the compound with the following structure, which is Proxelutamide (Pruxelutamide) intermediates.

Figure BDA0003730560390000091
Figure BDA0003730560390000091

还可进一步通过实施例来理解本发明,然而,要理解的是,这些实施例不限制本发明。现在已知的或进一步开发的本发明的变化被认为落入本文中描述的和以下要求保护的本发明范围之内。The invention can be further understood by the examples, however, it is to be understood that these examples do not limit the invention. Variations of the invention now known or further developed are considered to fall within the scope of the invention described herein and claimed below.

化合物15的HPLC检测方法如下:The HPLC detection method of compound 15 is as follows:

色谱柱:C18,150×4.6mm;柱温:25℃;流速:1.0mL/min;进样量:5μL;Chromatographic column: C18, 150×4.6mm; column temperature: 25°C; flow rate: 1.0mL/min; injection volume: 5μL;

检测波长:220nm;Detection wavelength: 220nm;

流动相:二元流动相体系:流动相A为0.02V%乙酸水溶液;流动相B为乙腈;Mobile phase: binary mobile phase system: mobile phase A is 0.02V% acetic acid aqueous solution; mobile phase B is acetonitrile;

洗脱方式:梯度洗脱(梯度洗脱过程中,流动相A的最大体积百分比为90%,最小体积百分比为0%)。Elution mode: gradient elution (during gradient elution, the maximum volume percentage of mobile phase A is 90%, and the minimum volume percentage is 0%).

实施例1化合物15的制备The preparation of embodiment 1 compound 15

Figure BDA0003730560390000092
Figure BDA0003730560390000092

向反应瓶中加入有机溶剂N,N-二甲基甲酰胺60ml、式11化合物12g,搅拌溶解,冰浴条件下滴加NBS的N,N-二甲基甲酰胺溶液40ml(NBS为式11化合物摩尔量的1.05倍),滴加结束后自然升温至室温,反应16-24h;反应结束后滴加亚硫酸氢钠水溶液淬灭多余的NBS,乙酸乙酯萃取(3×60ml),收集有机相,减压浓缩,得油状物的化合物12。Add 60ml of the organic solvent N,N-dimethylformamide and 12g of the compound of formula 11 into the reaction flask, stir to dissolve, and add 40ml of NBS N,N-dimethylformamide solution dropwise under ice bath conditions (NBS is the formula 11 1.05 times the molar weight of the compound), naturally warmed up to room temperature after the dropwise addition, and reacted for 16-24h; after the reaction was finished, aqueous sodium bisulfite solution was added dropwise to quench excess NBS, extracted with ethyl acetate (3 × 60ml), and the organic phase, concentrated under reduced pressure to obtain compound 12 as an oil.

向反应瓶中加入CuCN(为式11化合物摩尔量的1.1倍)、N,N-二甲基甲酰胺50ml,搅拌,20-30℃下将上述步骤所得化合物12全部滴加到反应瓶中,控制滴加时间为1-2h,滴加结束后升温至120-130℃反应6-8h;反应结束后降温至室温,然后加入50ml氨水溶液和二氯甲烷搅拌萃取(60ml×2),收集二氯甲烷层,然后采用饱和食盐水洗涤二氯甲烷层,收集有机层,浓缩至无馏分蒸出,得粗品,粗品采用60ml正庚烷在40-50℃下搅拌打浆6-8h后,过滤,干燥,得10.8g化合物15(HPLC面积归一化法测定其纯度为99.5%,保留时间为8.39min,HPLC图谱见图1),收率为80.0%(以化合物11投料量计算,且化合物15纯度以100%计算)。Add CuCN (1.1 times the molar amount of the compound of formula 11) and 50ml of N,N-dimethylformamide into the reaction flask, stir, and drop all the compound 12 obtained in the above steps into the reaction flask at 20-30°C, Control the dropwise addition time for 1-2h. After the dropwise addition, raise the temperature to 120-130°C for 6-8h; Chloromethane layer, then wash the dichloromethane layer with saturated brine, collect the organic layer, concentrate until no distillate is evaporated to obtain a crude product, which is stirred and beaten with 60ml of n-heptane at 40-50°C for 6-8h, then filtered, Dry to obtain 10.8g of compound 15 (the HPLC area normalization method measures its purity to be 99.5%, and the retention time is 8.39min, and the HPLC collection is shown in Figure 1), and the yield is 80.0% (calculated based on the compound 11 charging amount, and the compound 15 Purity is calculated as 100%).

申请人前期未对后处理进行优化,后处理过程中加入二氯甲烷与水,萃取,浓缩,得到产物纯度仅为83.3%,收率与上述方法基本相同。所以,后处理采取氨水联合正庚烷打浆可显著提高产品纯度,且产品损失较少。The applicant did not optimize the post-treatment in the early stage. During the post-treatment process, dichloromethane and water were added, extracted and concentrated. The purity of the product obtained was only 83.3%, and the yield was basically the same as the above method. Therefore, post-treatment using ammonia water combined with n-heptane beating can significantly improve product purity with less product loss.

实施例2Example 2

Figure BDA0003730560390000101
Figure BDA0003730560390000101

向反应瓶中加入化合物15(1.0g,4.9mmol)、N,N'-硫羰基二咪唑(1.75g,9.8mmol)、甲苯10ml和三乙胺(1.49g,14.7mmol),搅拌溶解,升温至80℃下反应6h,取样TLC监测,反应完全,停止加热,降温至室温。Add compound 15 (1.0g, 4.9mmol), N,N'-thiocarbonyldiimidazole (1.75g, 9.8mmol), 10ml of toluene and triethylamine (1.49g, 14.7mmol) into the reaction flask, stir to dissolve, and raise the temperature Reaction at 80°C for 6h, sampling by TLC monitoring, the reaction was complete, stop heating, and cool down to room temperature.

旋蒸除甲苯,采用色谱柱纯化(PE:EA=2:1,Rf=0.2-0.3),得式I所示化合物(1.13g),收率73.4%。Toluene was removed by rotary evaporation, and column purification (PE:EA=2:1, R f =0.2-0.3) was used to obtain the compound represented by formula I (1.13g), with a yield of 73.4%.

LC-MS:m/z 295.05[M+1]+LC-MS: m/z 295.05[M+1] + ;

1H NMR(400MHz,DMSO-d6):δ8.73(s,1H),8.41(d,J=8.4Hz,1H),8.30(d,J=8.4Hz,1H),8.12(s,1H),7.28(s,1H)。 1 H NMR (400MHz, DMSO-d6): δ8.73(s, 1H), 8.41(d, J=8.4Hz, 1H), 8.30(d, J=8.4Hz, 1H), 8.12(s, 1H) ,7.28(s,1H).

实施例3Example 3

Figure BDA0003730560390000102
Figure BDA0003730560390000102

向反应瓶中加入化合物15(2.0g,10mmol)、二硫化碳(0.91g,12mmol)、丙酮20ml和三乙烯二胺0.5ml(为化合物15摩尔量的0.45倍),搅拌溶解,升温至40-50℃下反应6-8h后,取样TLC监测,反应完全,停止加热,降温至室温。Add compound 15 (2.0g, 10mmol), carbon disulfide (0.91g, 12mmol), 20ml of acetone and 0.5ml of triethylenediamine (0.45 times the molar amount of compound 15) into the reaction flask, stir to dissolve, and heat up to 40-50 After reacting at ℃ for 6-8h, sampling TLC monitoring, the reaction is complete, stop heating, and cool down to room temperature.

旋蒸除丙酮,采用色谱柱纯化(PE:EA=2:1,Rf=0.2-0.3),得式II所示化合物。Acetone was removed by rotary evaporation, and column purification (PE:EA=2:1, R f =0.2-0.3) was used to obtain the compound represented by formula II.

LC-MS:m/z 258.92[M-1]-LC-MS: m/z 258.92 [M-1] - .

实施例4Example 4

Figure BDA0003730560390000111
Figure BDA0003730560390000111

按如上方法制备式A化合物,其中P为苯甲酰基。具体步骤为:Compounds of formula A, wherein P is benzoyl, are prepared as above. The specific steps are:

1)化合物15在硫氰酸铵和苯甲酰氯的存在下反应,后处理得到化合物15-1;1) Compound 15 was reacted in the presence of ammonium thiocyanate and benzoyl chloride, and post-treated to obtain compound 15-1;

2)化合物15-1在以氢氧化钠为碱、甲醇作为溶剂的情况下脱除苯甲酰基,后处理得到化合物15-2;2) Compound 15-1 removes the benzoyl group with sodium hydroxide as the base and methanol as the solvent, followed by post-treatment to obtain Compound 15-2;

3)化合物15-2在氯苯的溶剂体系内加热脱除氨气,生成目标产物式A化合物。3) Compound 15-2 is heated in a solvent system of chlorobenzene to remove ammonia to generate the target compound of formula A.

Claims (12)

1.一种制备化合物15的方法,所述方法包括:化合物12在溶剂和氰基化试剂的存在下反应生成化合物15,1. A method for preparing compound 15, said method comprising: compound 12 reacts to generate compound 15 in the presence of solvent and cyanation reagent,
Figure FDA0003730560380000011
Figure FDA0003730560380000011
2.根据权利要求1所述的方法,其特征在于:2. The method according to claim 1, characterized in that: 所述溶剂为极性有机溶剂,所述极性有机溶剂优选为腈类、亚砜类、链状酰胺类或环状酰胺类中任意一种或多种的组合,更优选为N,N-二甲基甲酰胺、N,N-二甲基乙酰胺、二甲基亚砜、乙腈或N-甲基吡咯烷酮中任意一种或多种的组合;The solvent is a polar organic solvent, and the polar organic solvent is preferably a combination of any one or more of nitriles, sulfoxides, chain amides or cyclic amides, more preferably N,N- Any one or more combinations of dimethylformamide, N,N-dimethylacetamide, dimethyl sulfoxide, acetonitrile or N-methylpyrrolidone; 所述氰基化试剂选自KCN、NaCN、CuCN、Zn(CN)2、Ni(CN)2、K4[Fe(CN)6]或K3[Fe(CN)6]中任意一种。The cyanation reagent is selected from any one of KCN, NaCN, CuCN, Zn(CN) 2 , Ni(CN) 2 , K 4 [Fe(CN) 6 ] or K 3 [Fe(CN) 6 ]. 3.根据权利要求2所述的方法,其特征在于:3. The method according to claim 2, characterized in that: 所述溶剂为N,N-二甲基甲酰胺,所述氰基化试剂为CuCN。The solvent is N,N-dimethylformamide, and the cyanation reagent is CuCN. 4.根据权利要求1-3中任一项所述的方法,其特征在于:4. The method according to any one of claims 1-3, characterized in that: 所述方法包括:将所述化合物12滴加到所述溶剂和所述氰基化试剂的体系中,滴加结束后升温反应;The method comprises: adding the compound 12 dropwise into the system of the solvent and the cyanation reagent, and raising the temperature to react after the dropping; 优选地,滴加过程中控制体系温度;Preferably, the temperature of the system is controlled during the dropping process; 更优选地,所述体系温度为10-50℃,进一步优选20-30℃。More preferably, the temperature of the system is 10-50°C, further preferably 20-30°C. 5.根据权利要求4所述的方法,其特征在于:5. The method according to claim 4, characterized in that: 所述氰基化试剂的摩尔量为所述化合物12的1.0-1.5倍,优选1.1、1.2、1.3或1.4倍,更优选1.1倍;The molar amount of the cyanation reagent is 1.0-1.5 times that of the compound 12, preferably 1.1, 1.2, 1.3 or 1.4 times, more preferably 1.1 times; 优选地,所述反应的温度为110-140℃,进一步优选120-130℃。Preferably, the reaction temperature is 110-140°C, more preferably 120-130°C. 6.根据权利要求4或5所述的方法,其特征在于:6. The method according to claim 4 or 5, characterized in that: 所述方法还包括后处理的步骤,所述后处理的步骤包括:向反应体系中加入有机相溶剂和水相溶剂,萃取,洗涤,浓缩有机相,即得;优选地,所述有机相溶剂为氯代烃,优选二氯甲烷;所述水相溶剂为水;The method also includes a post-treatment step, which includes: adding an organic phase solvent and an aqueous phase solvent to the reaction system, extracting, washing, and concentrating the organic phase to obtain; preferably, the organic phase solvent It is a chlorinated hydrocarbon, preferably methylene chloride; the aqueous phase solvent is water; 优选地,所述后处理的步骤包括:向反应体系中加入有机相溶剂和水相溶剂,萃取,洗涤,浓缩有机相,打浆,即得;优选地,所述有机相溶剂为氯代烃,优选二氯甲烷;所述水相溶剂为氨水;所述打浆采用烷烃来完成,优选正庚烷。Preferably, the step of post-processing includes: adding an organic phase solvent and an aqueous phase solvent to the reaction system, extracting, washing, concentrating the organic phase, beating, and obtaining that product; preferably, the organic phase solvent is a chlorinated hydrocarbon, Dichloromethane is preferred; the aqueous phase solvent is ammonia water; the beating is accomplished with alkanes, preferably n-heptane. 7.根据权利要求1所述的方法,其特征在于:7. The method of claim 1, wherein: 所述化合物12的制备方法包括:化合物11在有机溶剂和溴化试剂的存在下反应生成化合物12,The preparation method of the compound 12 comprises: reacting the compound 11 to generate the compound 12 in the presence of an organic solvent and a brominating reagent,
Figure FDA0003730560380000021
Figure FDA0003730560380000021
优选地,所述有机溶剂为链状或环状酰胺类中任意一种或多种的组合,优选N,N-二甲基甲酰胺或N,N-二甲基乙酰胺中的一种或两种的组合;Preferably, the organic solvent is any one or a combination of chain or cyclic amides, preferably one or more of N,N-dimethylformamide or N,N-dimethylacetamide a combination of the two; 优选地,所述溴化试剂为NBS、DBH、DBBA、NBP或TBCA;Preferably, the bromination reagent is NBS, DBH, DBBA, NBP or TBCA; 更优选地,所述有机溶剂为N,N-二甲基甲酰胺,所述溴化试剂为NBS;More preferably, the organic solvent is N,N-dimethylformamide, and the bromination reagent is NBS; 优选地,所述方法包括:将所述溴化试剂或者所述溴化试剂和所述有机溶剂的体系滴加到所述化合物11和所述有机溶剂的体系中,滴加结束后升温反应;Preferably, the method comprises: adding the bromination reagent or the system of the bromination reagent and the organic solvent dropwise to the system of the compound 11 and the organic solvent, and heating up the reaction after the dropwise addition; 优选地,滴加过程中控制体系温度;更优选地,所述体系温度为-5~5℃,进一步优选0℃。Preferably, the temperature of the system is controlled during the dropping process; more preferably, the temperature of the system is -5 to 5°C, further preferably 0°C.
8.根据权利要求1-7所述的方法,其特征在于:8. The method according to claims 1-7, characterized in that: 所述方法的具体步骤为:The concrete steps of described method are: 向反应瓶中加入N,N-二甲基甲酰胺、化合物11,搅拌溶解,冰浴条件下滴加NBS的N,N-二甲基甲酰胺溶液,滴加结束后自然升温至室温反应;反应结束后滴加亚硫酸氢钠水溶液,乙酸乙酯萃取,收集有机相,减压浓缩,得化合物12;Add N,N-dimethylformamide and compound 11 to the reaction flask, stir to dissolve, add NBS N,N-dimethylformamide solution dropwise under ice bath conditions, and naturally warm up to room temperature after the addition; After the reaction was completed, aqueous sodium bisulfite solution was added dropwise, extracted with ethyl acetate, the organic phase was collected and concentrated under reduced pressure to obtain compound 12; 向反应瓶中加入CuCN、N,N-二甲基甲酰胺,搅拌,将上述步骤所得的化合物12滴加到反应瓶中,控制滴加时间和温度,滴加结束后升温反应;反应结束后降温至室温,加入氨水和二氯甲烷,搅拌,萃取,收集二氯甲烷层,饱和食盐水洗涤二氯甲烷层,收集有机层,浓缩,得粗品,粗品采用正庚烷打浆得化合物15。Add CuCN and N,N-dimethylformamide to the reaction flask, stir, add the compound 12 obtained in the above steps into the reaction flask dropwise, control the time and temperature of the dropwise addition, and raise the temperature to react after the dropwise addition; Cool down to room temperature, add ammonia and dichloromethane, stir, extract, collect the dichloromethane layer, wash the dichloromethane layer with saturated brine, collect the organic layer, and concentrate to obtain a crude product, which is beaten with n-heptane to obtain compound 15. 9.一种制备式A所示异硫氰酸芳基酯化合物的方法,包括如下步骤:9. A method for preparing an aryl isothiocyanate compound shown in formula A, comprising the steps of:
Figure FDA0003730560380000031
Figure FDA0003730560380000031
其中,P为氨基保护基;Wherein, P is an amino protecting group; 1)化合物15在硫氰酸盐和氨基保护剂的存在下生成化合物15-1;优选地,所述化合物15由根据权利要求1-8中任一项所述的方法制备而成;1) Compound 15 generates compound 15-1 in the presence of thiocyanate and amino protecting agent; preferably, said compound 15 is prepared by the method according to any one of claims 1-8; 2)化合物15-1脱除氨基保护基,生成化合物15-2;2) Compound 15-1 removes the amino protecting group to generate compound 15-2; 3)化合物15-2脱除氨气,生成式A化合物;3) Compound 15-2 removes ammonia to generate a compound of formula A; 优选地,所述硫氰酸盐为硫氰酸铵、硫氰酸钠、硫氰酸钾、硫氰酸镁或硫氰酸锰中的任意一种,更优选硫氰酸铵;Preferably, the thiocyanate is any one of ammonium thiocyanate, sodium thiocyanate, potassium thiocyanate, magnesium thiocyanate or manganese thiocyanate, more preferably ammonium thiocyanate; 优选地,所述氨基保护基为烷氧羰基、酰基或烷基中的任意一种;进一步优选地,所述烷氧羰基为苄氧羰基、叔丁氧羰基、芴甲氧羰基、烯丙氧羰基或三甲基硅乙氧羰基中任意一种;所述酰基为邻苯二甲酰基、对甲苯磺酰基、三氟乙酰基或苯甲酰基中任意一种,更优选苯甲酰基;所述烷基为三苯甲基、2,4-二甲氧基苄基、对甲氧基苄基或苄基中任意一种。Preferably, the amino protecting group is any one of alkoxycarbonyl, acyl or alkyl; further preferably, the alkoxycarbonyl is benzyloxycarbonyl, tert-butoxycarbonyl, fluorenylmethyloxycarbonyl, allyloxy Any one of carbonyl or trimethylsilylethoxycarbonyl; said acyl is any one of phthaloyl, p-toluenesulfonyl, trifluoroacetyl or benzoyl, more preferably benzoyl; said The alkyl group is any one of trityl, 2,4-dimethoxybenzyl, p-methoxybenzyl or benzyl.
10.一种制备式A所示异硫氰酸芳基酯化合物的方法,所述方法包括:化合物12在溶剂和氰基化试剂的存在下反应生成化合物15,化合物15通过根据权利要求9所述的方法生成式A所示化合物,10. A method for preparing an aryl isothiocyanate compound shown in formula A, said method comprising: compound 12 reacts to generate compound 15 in the presence of a solvent and a cyanation reagent, and compound 15 passes through according to claim 9 Described method generates the compound shown in formula A,
Figure FDA0003730560380000032
Figure FDA0003730560380000032
优选地,所述化合物15由根据权利要求1-8中任一项所述的方法制备而成。Preferably, the compound 15 is prepared by the method according to any one of claims 1-8.
11.化合物15在制备具有式I或式II所示结构的化合物中的用途,其中,所述化合物15由根据权利要求1-8中任一项所述的方法制备而成:11. The use of compound 15 in the preparation of compounds having the structure shown in formula I or formula II, wherein the compound 15 is prepared by the method according to any one of claims 1-8:
Figure FDA0003730560380000041
Figure FDA0003730560380000041
12.一种制备式II所示化合物的方法,所述方法包括:以化合物15为原料,以二硫化碳为反应试剂,在有机碱和有机溶剂的存在下反应生成式II所示化合物,12. A method for preparing a compound shown in formula II, said method comprising: using compound 15 as a raw material, taking carbon disulfide as a reagent, reacting to generate a compound shown in formula II in the presence of an organic base and an organic solvent,
Figure FDA0003730560380000042
Figure FDA0003730560380000042
优选地,所述化合物15由根据权利要求1-8中任一项所述的方法制备而成;Preferably, the compound 15 is prepared by the method according to any one of claims 1-8; 优选地,所述有机碱为三乙胺、吡啶、N,N-二异丙基乙胺、三乙烯二胺、1,5-二氮杂双环[4.3.0]壬-5-烯、1,8-二偶氮杂双螺环[5.4.0]十一-7-烯、4-二甲氨基吡啶、N-甲基吗啉、四甲基乙二胺中的至少一种,更优选三乙烯二胺;Preferably, the organic base is triethylamine, pyridine, N,N-diisopropylethylamine, triethylenediamine, 1,5-diazabicyclo[4.3.0]non-5-ene, 1 , At least one of 8-diazabispiro[5.4.0]undec-7-ene, 4-dimethylaminopyridine, N-methylmorpholine, tetramethylethylenediamine, more preferably Triethylenediamine; 优选地,所述有机溶剂为烷基酮类,更优选为丙酮、丁酮或甲基异丁基酮,进一步优选丙酮;Preferably, the organic solvent is an alkyl ketone, more preferably acetone, butanone or methyl isobutyl ketone, more preferably acetone; 优选地,所述二硫化碳的摩尔量为所述化合物15的1-3倍,更优选1.2、1.5或2.0倍,进一步优选1.2倍;Preferably, the molar amount of carbon disulfide is 1-3 times that of compound 15, more preferably 1.2, 1.5 or 2.0 times, further preferably 1.2 times; 优选地,所述有机碱的摩尔量为所述化合物15的0.1-1倍,更优选为0.2-0.8倍,进一步优选0.4-0.5倍。Preferably, the molar amount of the organic base is 0.1-1 times that of the compound 15, more preferably 0.2-0.8 times, further preferably 0.4-0.5 times.
CN202210791874.8A 2021-07-06 2022-07-05 A kind of preparation method of aryl isothiocyanate Pending CN115583898A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202110763447 2021-07-06
CN2021107634474 2021-07-06

Publications (1)

Publication Number Publication Date
CN115583898A true CN115583898A (en) 2023-01-10

Family

ID=84772599

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202210791874.8A Pending CN115583898A (en) 2021-07-06 2022-07-05 A kind of preparation method of aryl isothiocyanate

Country Status (1)

Country Link
CN (1) CN115583898A (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118496163A (en) * 2024-05-08 2024-08-16 奥锐特药业股份有限公司 A preparation method of enzalutamide and its intermediates
CN118496163B (en) * 2024-05-08 2025-02-25 奥锐特药业股份有限公司 A preparation method of enzalutamide and its intermediates

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102482230A (en) * 2009-09-10 2012-05-30 童友之 Androgen receptor antagonists and uses thereof
CN105308025A (en) * 2013-05-20 2016-02-03 杜邦公司 Solid forms of fungicidal pyrazoles
WO2021133894A1 (en) * 2019-12-23 2021-07-01 Biogen Ma Inc. Btk inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102482230A (en) * 2009-09-10 2012-05-30 童友之 Androgen receptor antagonists and uses thereof
CN105308025A (en) * 2013-05-20 2016-02-03 杜邦公司 Solid forms of fungicidal pyrazoles
WO2021133894A1 (en) * 2019-12-23 2021-07-01 Biogen Ma Inc. Btk inhibitors

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118496163A (en) * 2024-05-08 2024-08-16 奥锐特药业股份有限公司 A preparation method of enzalutamide and its intermediates
CN118496163B (en) * 2024-05-08 2025-02-25 奥锐特药业股份有限公司 A preparation method of enzalutamide and its intermediates

Similar Documents

Publication Publication Date Title
CA2698245C (en) Process and intermediates for preparing integrase inhibitors
KR101096499B1 (en) Method of manufacturing telmisartan
TWI697495B (en) Synthesis of copanlisib and its dihydrochloride salt
CN108383749B (en) Synthetic method of apaluamide and intermediate thereof
JP2016065058A5 (en)
CN113666909B (en) Topiroxostat preparation method
TW201625633A (en) Synthesis of COPANLISIB and its dihydrochloride salt
CN106699570A (en) Synthesis method for (2-chloro-5-iodophenyl)(4-fluorophenyl)ketone
CN108623567A (en) Ao Si replaces the preparation method of Buddhist nun
CN114751894A (en) Preparation method of oral medicine for treating neocoronary pneumonia
CN115583898A (en) A kind of preparation method of aryl isothiocyanate
IT201800005874A1 (en) PROCESS FOR THE PREPARATION OF APALUTAMIDE
CN111377864A (en) Lovatinib impurity and preparation method and application thereof
WO2014067237A1 (en) Telmisartan preparation method and intermediate thereof
CN107021930B (en) Synthesize 1H, 1`H-(2,2`- bisbenzimidazole) -5,5`- diamines method
WO2022206742A1 (en) Method for synthesizing thiohydantoin derivative by means of one-step method
CN110615823B (en) Preparation method of (2 'R) -2' -deoxidized-2 '-fluoro-2' -methyluridine
WO2018122724A1 (en) Temozolomide process
CN113024412A (en) Preparation method of 2,4, 6-trichlorobenzonitrile
CN110770231B (en) Preparation method of tyrosine kinase inhibitor and intermediate thereof
RU2828349C1 (en) METHOD OF PRODUCING DIHALOGEN DERIVATIVE OF 1,2,3,4-TETRAHYDROPYRIDO- OR PYRIDO[1,2-a]BENZIMIDAZOLE-6,9-DIONE
CN114249677B (en) Riluzole intermediate compound and preparation method thereof
CN102911129A (en) Method for preparing substituted tetrazole compound
CN113773235B (en) Synthesis method of clorsulon
Jadhao et al. Copper-mediated [3+ 2] oxidative cyclization of oxime acetate and its utility in the formal synthesis of fentiazac

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20230110